Retinalamin® refers to the pharmacotherapeutic stimulators of tissue regeneration. The mechanism of action is determined by the metabolic activity of Retinalamin®: the drug activates eye tissue metabolism, normalizes the functions of cellular membranes, improves intracellular synthesis of protein, regulates the processes of lipid peroxide oxidation, and optimizes energy processes due to strengthened activity of Muller’s cells and glutamate inactivation. It improves the functional interaction between the pigment epithelium and outer segments of visual receptors, normalizes vascular permeability, prevents oxidative stress and excitotoxicity, improves metabolism in ocular tissues and blood flow in ocular vessels.
GEROPHARM is the only manufacturer of original drug Retinalamin® (link to the official site of the State Register of Medicines – http://grls.rosminzdrav.ru/grls.aspx).
This drug is a prescribed medicine. It can be dispensed on a doctor's prescription only. There are contraindications. Please read the patient information leaflet. Do not use the medicinal agent if it was not prescribed by your treating physician. Always follow the patient information leaflet and your doctor’s recommendations.
Retinoprotectors are agents that protect retina from damage caused by exogenous and endogenous forces thus safeguarding eyesight from getting worse. Searching new retinoprotectors is a complex process that requires combined effort of doctors, biologists and pharmacologists. Peptides need special attention. Their advantage consists in tissue specificity, lack of pronounced adverse effects, short treatment duration and long-term clinical effect. Retinalamin®, a drug with proven cellular and molecular effectiveness, is an example of successful development based on the abovementioned principles. Retinal damages vary in causes and clinical picture. They are united by the concurrent death of retinal neurons due to pathological processes with similar molecular mechanisms. Excitotoxicity caused by excessive activation of glutamate receptors and subsequent entry of calcium ions into a cell is a key mechanism. Excess of calcium launches processes resulting in necrotic and apoptotic cell death.
Retinalamin® is a complex of water-soluble polypeptide fractions with the molecular weight of no more than 10 kDa. Pharmacotherapeutic group: stimulator of tissue regeneration.
Retinalamin® is a retinoprotector that produces a direct effect on the retina. It launches mechanisms of adaptation and regeneration of retinal neurons to the pathological process improving visual functions in glaucoma, diabetic retinopathy and other disorders of the eye.
Trade name: RETINALAMIN®
Grouping name: cattle retinal polypeptides.
Dosage form: lyophilisate for preparation of solution for intramuscular and parabulbar injections.
Composition Each vial contains: drug substance – Retinalamin 5 mg (complex of water-soluble polypeptide fractions), excipient – Glycine 17 mg (stabilizer).
Pharmacotherapeutic group: stimulator of tissue regeneration.
ATC code: S01XA.
Pharmacodynamics: Retinalamin is a complex of water-soluble polypeptide fractions with the molecular weight of no more than 10,000 kDa. The agent has a stimulating effect on retinal photoreceptors and cellular elements, improves functional interaction between pigment epithelium and outer segments of photoreceptors, glial cells in patients with retinal dystrophy and accelerates recovery of light sensitivity processes in the retina. It normalizes vascular permeability, reduces local inflammation, and activates reparative processes in patients with diseases and traumas of the retina.
Indications for use: compensated primary open-angle glaucoma, diabetic retinopathy, post-traumatic and post-inflammatory central retinal dystrophy, central retinal dystrophy, myopia (within comprehensive treatment), central and peripheral tapetoretinal abiotrophy.
Contraindications: individual hypersensitivity to any of the medication components, in patients under 18 with compensated primary open-angle glaucoma, diabetic retinopathy, myopia (due to lack of efficacy and safety data); in patients under 12 months with post-traumatic and post-inflammatory central retinal dystrophy, central and peripheral tapetoretinal abiotrophy.
Directions for use and dosage: in adults with diabetic retinopathy, post-traumatic and post-inflammatory central retinal dystrophy, central and peripheral tapetoretinal abiotrophy: parabulbar or intramuscular injections of 5–10 mg once a day. Treatment duration is 5–10 days; if necessary, it is repeated after 3–6 months. In patients with compensated primary open-angle glaucoma: parabulbar or intramuscular injections of 5 mg once a day. Treatment duration is 10 days; if necessary, it is repeated after 3–6 months. In patients with myopia: parabulbar injections of 5 mg once a day. Treatment duration is 10 days. In children at the age of 1–5 years with post-traumatic and post-inflammatory central retinal dystrophy, central and peripheral tapetoretinal abiotrophy: parabulbar or intramuscular injections of 2.5 mg once a day. In children at the age of 6–18 years with post-traumatic and post-inflammatory central retinal dystrophy, central and peripheral tapetoretinal abiotrophy: parabulbar or intramuscular injections of 2.5–5.0 mg once a day. Dissolve the medicinal agent in 1–2 ml of 0.9 % solution of sodium chloride, directing the needle toward the side of the vial to avoid foaming. Treatment duration is 10 days; if necessary, it is repeated after 3–6 months.
Possible adverse effects: adverse effects are not reported. Allergic reactions are possible in case of individual intolerance to any component of the medication.
Shelf-life: 3 years.
Storage conditions: protected from light at 2–20 °C. Dosage form: Lyophilisate for preparation of solution for intramuscular and parabulbar injections, 5 mg.
Dispensing conditions: by prescription.
Registration number: ЛС-000684
Company that accepts claims from the customers:
Please read the patient information leaflet for detailed information on the drug.
Warrantied high quality of released medicinal agents and customer satisfaction is a priority of GEROPHARM which is one of the leading Russian manufacturers. The company follows the latest tendencies of the pharmaceutical market including packaging of pharmaceutical drugs and introduces the most innovation agents.
Modernization of the production line was completed in 2014. It enabled to produce agents with higher consumer properties. Nowadays Retinalamin® is released in a new improved package warranting that the agent is unique and convenient in use.
Barcode applied onto the vial label, patient information leaflet and package offers an additional warranty that the package, the drug herein and it dosage correspond to the enclosed leaflet. The package is also supplied with a perforated flap to control the first opening and provide better protection from a counterfeit product.
A closed blister with vials is introduced for the same purpose. Apart from the first opening control, it makes the use of the agent more convenient. Now it is possible to have one closed blister. Besides, opening a blister is easy. A more dense and flexible PVC film of the lodgment with vials has no sharp edges. It protects hands from being injured.
Package labeling (indication of a lot and expiry date) is now done using an expensive laser printer. It makes the label more resistant to discoloration and spilling. Even people with impaired vision can read the name of the medicinal drug owing to Braille script.
Package upgrade is an important element of GEROPHARM marketing strategy which is aimed at optimum satisfaction of consumers and getting ahead of their needs.